Targeted Protein Degradation (TPD) technology has rapidly evolved over the past two decades as a method to disrupt protein function. The aim of this technology is to selectively degrade specific proteins, thereby modulating cellular processes and signaling pathways.

Nanobodies are regarded as promising strategies and tools in both targeted detection and clinical treatment fields. However, research on targeted detection and clinical treatment of Helicobacter pylori (HP) primarily focuses on peptides, single-chain antibodies (scFv), yolk antibodies, and monoclonal antibodies. Despite their high affinity, good stability, low immunogenicity, small molecular size, and ease of modification, there have been no significant reports on the development of effective nanobody drugs for targeting Helicobacter pylori.

Recently, Johnson & Johnson (JNJ) announced that its developed bispecific antibody, Rybrevant (amivantamab), has received full approval from the U.S. FDA for its use in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.

         Winter is the peak season for acute cardiovascular and cerebrovascular events. Cold weather can lead to elevated blood pressure and cerebral vasospasm, increasing the likelihood of cerebrovascular disease. Myocardial infarction and sudden cardiac death are also associated with cold temperatures. Studies have shown that for every 1°C decrease in temperature, the incidence of heart disease increases by approximately 2%. Traditional treatment strategies typically involve methods such as reducing fat, improving metabolism, dilating blood vessels, or clearing vascular blockages. However, these strategies still have many limitations.